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Abstract  
A novel multifunctional nanodevice based in doxorubicin (DOX)-loaded mesoporous silica 
nanoparticles (MSNs) as nanoplatforms for the assembly of different building blocks has been 
developed for bone cancer treatment. These building blocks consists of: i) a polyacrylic acid 
(PAA) capping layer grafted to MSNs via an acid-cleavable acetal linker, to minimize premature 
cargo release and provide the nanosystem of pH-responsive drug delivery ability; and ii) a 
targeting ligand, the plant lectin concanavalin A (ConA), able to selectively recognize, bind and 
internalize owing to certain cell-surface glycans, such as sialic acids (SA), overexpressed in given 
tumor cells. This multifunctional nanosystem exhibits a noticeable higher internalization degree 
into human osteosarcoma cells (HOS), overexpressing SA, compared to healthy preosteoblast cells 
(MC3T3-E1). Moreover, the results indicate that small DOX loading (2.5 µg mL-1) leads to almost 
100% of osteosarcoma cell death in comparison with healthy bone cells, which significantly 
preserve their viability. Besides, this nanodevice has a cytotoxicity on tumor cells 8-fold higher 
than that caused by the free drug. These findings demonstrate that the synergistic combination of 
different building blocks into a unique nanoplatform increases antitumor effectiveness and 
decreases toxicity towards normal cells. This line of attack opens up new insights in targeted bone 
cancer therapy. 
STATEMENT OF SIGNIFICANCE 
The development of highly selective and efficient tumor-targeted smart drug delivery 
nanodevices remains a great challenge in nanomedicine. This work reports the design and 
optimization of a multifunctional nanosystem based on mesoporous silica nanoparticles 
(MSNs) featuring selectivity towards human osteosarcoma cells and pH-responsive 
antitumor drug delivery capability. The novelty and originality of this manuscript relies on 
proving that the synergistic assembly of different building blocks into a unique 
nanoplatform increases antitumor effectiveness and decreases toxicity towards healthy 
cells, which constitutes a new paradigm in targeted bone cancer therapy. 
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1. Introduction 
The major constraint of conventional chemotherapy for cancer treatment is the lack of specificity 
of cytotoxic drugs. This constitutes a serious threat to healthy tissues, resulting in a significant 
decrease of the efficacy and provoking the apparition of side-effects in the patient associated to 
systemic toxicity[1]. The emergence of nanotechnology has transformed this scenario owing to the 
development of nanocarriers for therapeutic agents[2]. Particularly, in the last two decades much 
research effort has been devoted to build nanocarriers for tumor-targeted stimuli-responsive drug 
delivery[3-7].  
Among nanocarriers, mesoporous silica nanoparticles (MSNs) are receiving growing interest since 
they exhibit unique properties such as large surface areas and pore volumes, which provide high 
loading capability, customized sizes, morphology and pore diameters, robustness and easy 
functionalization[8-19]. Moreover, they exhibit low cytotoxicity[20] and good 
hemocompatibility[21]. These features provide exceptional opportunities to host different 
therapeutic payloads. Hence, the tunable surface of MSNs chemistry allows the attachment of 
organic functionalities such as pore blocking agents to avoid premature cargo release, or targeting 
ligands to guide MSNs towards diseased tissues.   
In this sense, during the last few years, a wide range of stimuli-responsive drug delivery systems, 
achieving release profiles with spatial, temporal and dosage control have been reported[4,15,17]. 
The performance of these smart nanosystems relies on triggering drug release at the target site by 
using moieties that are sensitive to external stimuli (light, magnetic fields, electric fields, 
ultrasounds, etc.)[22-30], internal stimuli (variations in pH, redox potential, or the concentrations 
of enzymes or specific analytes)[31-36], or combination of both[37]. However, the side effects in 
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most of these nanosystems cannot be disregarded in practice because these particles frequently 
lack of specific cancer cell targeting capability and can be also internalized by normal cells. In the 
last decade, considerable research effort has been committed to develop tumor-targeted stimuli-
responsive drug delivery systems. Although diverse targeting ligands, such as 
transferrin[23,35,38], certain peptides[39], hyaluronic acid[40,41], or folic acid[31,42], have been 
incorporated into stimuli-responsive MSNs, the development of highly selective and efficient 
tumor-targeted smart drug delivery nanodevices remains a tremendous challenge. Among the 
different antitumor drugs, doxorubicin (DOX) is receiving great attention because it is commonly 
used in the treatment of many types of cancer [43], including osteosarcoma bone tumors [44]. In 
this sense, much research effort is being devoted to design smart DOX-loaded MSNs aimed at 
overcoming the main limitation of conventional administered DOX in chemotherapy, i.e. its 
significant systemic toxicity [23,45-51]. However, to the best of our knowledge, none of them 
incorporates stimuli-responsive DOX release and targeting elements to distinguish between 
healthy and tumor bone cells for the efficient development of targeted bone cancer therapies.   
Herein we have designed and developed a multifunctional nanodevice based in DOX-loaded 
MSNs acting as nanoplatforms for the assembly of different building blocks: i) a pH-sensitive 
layer consisting in polyacrylic acid (PAA) anchored to the MSNs surface via an acid-cleavable 
acetal linker.[52].PAA was used as pore blocking agent due to its good properties such as 
biocompatibility, hydrophilicity and abundance of carboxylic groups prone to experience easy 
functionalization[53]; and ii) a targeting ligand, the lectin concanavalin A (ConA) grafted to PAA, 
to increase the selectivity of the nanocarrier towards cancer cells and preserve the viability of 
healthy cells. ConA was chosen as targeting ligand owing the capability of this plant lectin to 
selectively recognize and bind to cell-surface glycans, which are frequently overexpressed in 
cancer cells[54,55].   
The pH-responsive drug delivery performance of the nanosystem was evaluated “in vial” using 
[Ru(bipy)3]2+ as model molecule. The results demonstrate that in acidic conditions (pH 5.3) 
mimicking those of endo/lysosomes drug released is faster than in physiological conditions (pH 
7.4). Then, the capacity of this multifunctional nanodevice to selectively eradicate human 
  
5 
 
osteosarcoma cancer cells (HOS), overexpressing sialic acid (SA) glycans as ConA receptors, 
compared to healthy preosteoblastic cells (MC3T3-E1), non-overexpressing SA, was in vitro 
evaluated. The results indicate the preferential internalization of the nanosystems into tumor cells 
and that only very small DOX concentrations are needed to almost completely eradicate 
osteosarcoma cells meanwhile preserving the viability of healthy bone cells. This resulted in a 
100% killing efficacy against tumor cells in comparison with normal cells, as well as 8-fold higher 
tumor cytotoxicity than that caused by free DOX. We envision this novel multifunctional 
nanodevice as a potential candidate to be incorporated into a nanomedicines library for targeted 
bone cancer therapy.  
  
 
 
2. Materials and Methods 
2.1 Reagents 
Tetraethylorthosilicate (TEOS, 98%), n-cetyltrimethylammo-nium bromide (CTAB, ≥ 99%), 
sodium hydroxide (NaOH, ≥ 98%), ammonium nitrate (NH4NO3, ≥ 98%), sodium carbonate 
(Na2CO3, ≥ 99,5%), hydrochloric acid (HCl, 37%), fluorescein 5(6)-isothiocyanate (FITC, ≥ 98%), 
(3-aminopropyl) triethoxysilane (APTES, ≥ 98%), N-(3-Dimethylaminopropyl)-N′-
ethylcarbodiimide hydrochloride (EDC, ≥ 98%), N-Hydroxysulfosuccinimide sodium salt (sulfo-
NHS, ≥ 98%), poly(acrylic acid) partial sodium salt solution (PAA, average Mw ~ 240,000 by 
GPC, 25 wt.% in H2O), phosphate-buffered saline (PBS, 10x), phosphotungstic acid hydrate (PTA, 
reagent grade), Concanavalin A from Canavalia ensiformis (Jack bean) (ConA, Type VI 
lyophilized powder), tris(bipyridine)ruthenium(II) chloride ([Ru(bipy)3]Cl2), and doxorubicin 
hydrochloride (DOX, European Pharmacopoeia) were purchased from Sigma-Aldrich (St. Louis, 
USA). 3-(Triethoxysiyl)propylsuccinic anhydride (TEPSA, 95%) was purchased from ABCR 
(Karlsruhe, Germany) and 3,9-Bis(3-aminopropyl)-2,4,8,10-tetraoxaspiro [5.5] undecane (ATU) 
was purchased from TCY (Tokyo, Japan). All other chemicals were purchased from Panreac 
Química SLU (Castellar del Valles, Barcelona, Spain) inc: absolute ethanol, acetone, dimethyl 
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sulfoxide (DMSO), etc. All reagents were used as received without further purification. Ultrapure 
deionized water with resistivity of 18.2 MΩ was obtained using a Millipore Milli-Q plus system 
(Millipore S.A.S, Molsheim, France). 
2.2 Characterization techniques 
Powder X-Ray Diffraction (XRD) experiments were performed in a Philips X’Pert diffractometer 
equipped with Cu Kα radiation (wavelength 1.5406 Å) (Philips Electronics NV, Eindhoven, 
Netherlands). XRD patterns were collected in the 2ɵ range between 0.6° and 8° with a step size of 
0.02° and counting time of 5 s per step. Thermogravimetric (TG measurements were performed in 
a Perkin Elmer Pyris Diamond TG/DTA (California, USA), with 5 ºC min-1 heating ramps, from 
room temperature (RT) to 600 ºC. Fourier transform infrared spectroscopy (FTIR) was carried out 
in a Nicolet (Thermo Fisher Scientific, Waltham, MA, USA) Nexus spectrometer equipped with a 
Goldengate attenuated total reflectance (ATR) accessory (Thermo Electron Scientific Instruments 
LLC, Madison, WI USA). Morphology, mesoestructural order and nanoparticles functionalization 
were studied by High Resolution Transmission Electron Microscopy (HRTEM) with a JEOL JEM 
3000F instrument operating at 300 kV, equipped with a CCD camera (JEOL Ltd., Tokyo, Japan). 
Sample preparation was performed by dispersing in distilled water and subsequent deposition onto 
carbon-coated copper grids. A 1% PTA solution (pH 7.0) was used as staining agent in order to 
visualize the organic coating around MSNs.  
To determine the evolution of the size and surface charge of nanoparticles by dynamic light 
scattering (DLS) and zeta (ζ)-potential measurements, respectively, a Zetasizer Nano ZS (Malvern 
Instruments, United Kingdom) equipped with a 633 nm “red” laser was used. DLS measurements 
were directly recorded in ethanolic colloidal suspensions. ζ-potential measurements were recorded 
in aqueous colloidal suspensions. For this purpose, 1 mg of nanoparticles was added to 10 mL of 
solvent followed by 5 min of sonication to obtain a homogeneous suspension. In both cases, 
measurements were recorded by placing 1 mL of suspension (0.1 mg mL-1) in DTS1070 
disposable folded capillary cells (Malvern Instruments). The textural properties of the materials 
were determined by N2 adsorption porosimetry by using a Micromeritics ASAP 2020 
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(Micromeritics Co., Norcross, USA). To perform the N2 measurements, 20-30 mg of each sample 
was previously degassed under vacuum for 24 h at 40 ºC temperature. The surface area (SBET) was 
determined using the Brunauer-Emmett-Teller (BET) method and the pore volume (VP) was 
estimated from the amount of N2 adsorbed at a relative pressure around 0.97. The pore size 
distribution between 0.5 and 40 nm was calculated from the adsorption branch of the isotherm by 
means of the Barrett-Joyner-Halenda (BJH) method. The mesopore size (DP) was determined from 
the maximum of the pore size distribution curve. To evaluate the different carbon environments, 
1H  13C CP (cross-polarization)/ MAS (magic angle spinning) solid-state nuclear magnetic 
resonance (NMR) measurements were performed in a Bruker AV-400-WB spectrometer 
(Karlsruhe, Germany) operating at 75.45 MHz. Solid samples were placed in a 4 mm zirconia 
rotor and spun at 12 kHz. Chemical shifts (δ) of 13C were externally referred to glycine at δ = 0.0 
ppm. The periods of time between successive accumulations were 3 ms and ca 15,000 scans were 
collected. 
2.3 Synthesis of pure-silica MSNs (MSN) 
Bare MSNs, denoted as MSN, were synthesized by the modified Stöber method using TEOS as 
silica source in the presence of CTAB as structure directing agent. Briefly, 1 g of CTAB, 480 mL 
of H2O and 3.5 mL of NaOH (2 M) were added to a 1,000 mL round-bottom flask. The mixture 
was heated to 80 ºC and magnetically stirred at 600 rpm. When the reaction mixture was stabilized 
at 80 ºC, 5 mL of TEOS were added dropwise at 0.33 mL min-1 rate. The white suspension 
obtained was stirred during further 2 h at 80 ºC. The reaction mixture was centrifuged and washed 
three times with water and ethanol. Finally, the product was dried under vacuum at 40 ºC. The 
surfactant was removed by ionic exchange by soaking 1 g of nanoparticles in 500 mL of a 
NH4NO3 solution (10 mg mL-1) in ethanol (95%) at 65 ºC overnight under magnetic stirring. The 
nanoparticles were collected by centrifugation (9,000 rpm, 15 min), washed twice with water and 
twice with ethanol and dried under vacuum at 40 ºC.  
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For cellular internalization studies fluorescein-labeled MSN were synthesized. For this purpose, 1 
mg FITC and 2.2 µL APTES were dissolved in 100 µL ethanol and left reacting for 2 h. Then the 
reaction mixture was added with the 5 mL of TEOS as previously described. 
2.4. Functionalization of MSN with carboxylic acid groups (MSNCOOH) 
With the aim of preferentially grafting carboxylic acid groups to the external surface of MSN, 
functionalization was carried out in MSN before being submitted to the surfactant extraction 
process [56]. Thus, 500 mg of CTAB-containing MSN were placed in a three-neck round bottom 
flask and dried at 80 ºC under vacuum for 24 h. Then, 125 mL of dry toluene was added and the 
flask was placed in an ultrasonic bath for several sonication cycles of 5 min until a good 
nanoparticles suspension was achieved. After that 300 µL of TEPSA were added, keeping the 
reaction under nitrogen atmosphere at 90 ºC for 24 h. Next, 40 mL of slightly acidified water were 
added in order to hydrolyze the succinic groups to carboxylic acid groups[57]. The nanoparticles 
were collected by centrifugation, washed three times with ethanol and dried under vacuum at 40 
ºC. For deep characterization of this carboxylic acid MSNs, the surfactant removal was 
accomplished by solvent extraction as above mentioned, affording MSNCOOH.   
2.5. Functionalization of MSN with a pH-cleavable linker (MSNATU) 
First, 300 mg of MSNCOOH was suspended in 50 mL PBS 1x and subjected to several sonication 
cycles of 5 min until a good suspension was achieved. Then, 480 mg of EDC and 180 mg of sulfo-
NHS was added and stirred for 30 min. After that, the grafting of ATU to the surface of surfactant-
containing MSNCOOH was attained by adding 2 g of ATU to the suspension and the mixture was 
reacted overnight. The product was filtered, washed with water and the surfactant removal was 
then carried out, affording MSNATU. This sample was left to dry under vacuum at 40 ºC. 
2.6. Capping of MSN with PAA (MSNPAA) 
The first step was to investigate the amount of acid-sensitive polymer that led to the most effective 
and uniform coating while avoiding nanoparticles aggregation. With this goal in mind 10 mg of 
MSNATU was suspended in 1 mL PBS (10 mM). Then 0.36, 3.6 or 36 µL PAA was added to the 
suspension and the resulting PAA-coated MSNs were characterized by TEM and their molecule 
  
9 
 
release performance was preliminary evaluated “in vial”, as it will be described below. The most 
effective and most uniform coating (Fig. S1, Supporting Information) and the best preliminary 
release behavior (results not shown) were achieved for the lowest polymer amount, i.e. 0.36 µL. 
Thus, this amount was chosen to synthetize PAA-coated nanoparticles, named MSNPAA. 
2.7. ConA grafting to MSNPAA (MSNConA) 
The covalent conjugation of ConA to MSNPAA nanoparticles was acomplished using a well-known 
and widely reported procedure, via carbodiimide chemistry, whereby the amine of the protein 
forms and amide bond to the carboxylated nanoparticle, affording MSNConA [58,59]. For this 
purpose, 16 mg of MSNPAA was placed in a vial and suspended in 2 mL of PBS pH 7.4 with the 
aid of several cycles of sonication. After that, 30 mg of EDC were added and the mixture was 
stirred at RT for 40 min. Then 14 mg of NHS were added and the reaction was stirred for 10 min 
before adding 30 mg of ConA and left to react overnight at RT. Finally, samples were filtered, 
washed twice with PBS pH 7.4 and dried under vacuum at 25 ºC. 
2.8. Cargo loading 
40 mg of MSNATU were placed in a dark glass vial and dried at 80 ºC overnight under vacuum. 
Then, 6 mL of [Ru(bipy)3]Cl2 (a model molecule) or DOX (an antitumor drug) aqueous solution 
(10 or 3 mg mL-1 respectively) were added and the suspension was stirred at RT. for 24 h. After 
that, 2.15 µL of PAA were added and stirred for 10 min before adding 96 mg of EDC and 36 mg 
of NHS and finally allowed to react overnight at RT. Next, samples were filtered and washed 
twice with PBS pH 7.4 in order to remove the [Ru(bipy)3]Cl2 or DOX adsorbed on the external 
surface of the nanoparticles. Finally, the products were dried under vacuum at 25 ºC. The grafting 
of ConA was then carried out by following the procedure previously described, leading to 
MSNConA@[Ru(bipy)3]2+ or MSNConA@DOX nanoparticles.  
The amount of [Ru(bipy)3]2+ or DOX loaded in nanoparticles was determined from the difference 
between the fluorescence measurements of the initial and the recovered filtrate solutions in the 
step previous to ConA grafting. In both cases, two different calibration lines (one at each tested 
pH) were performed to eliminate the contribution of nonspecific release by pH effect.  
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2.9. “In vial” cargo release assays 
To investigate the pH-responsive drug release performance of MSNConA, [Ru(bipy)3]2+ was chosen 
as model molecule and “in vial” time-based fluorescence release experiments in phosphate 
buffered saline (PBS 1x), at the two different pH values, i.e. 7.4 and 5.3, were carried out during 
24 h. Fluorescence measurements were recorded on a PTI QuantaMaster 400 system featuring a 
JYF-FLUOROMAX-4 compact spectrofluorimeter single grating excitation and emission 
monochromator with a photomultiplier detector (PMT R928P) and an automated four-position 
thermostated cuvette-holder (FL-1011) (PTI, Photon Technology International, HORIBA Jobin 
Yvon GmbH, Germany). For temperature settings, a MTB-IFI-156-5251 refrigerated bath 
circulator with a peltier was used. [Ru(bipy)3]2+ was excited with 451 nm and showed a maximum 
of emission at 619 nm (excitation slit 0.38 mm, emission slit 0.38 mm, integration 0.5 s). For 
release experiments, the procedure reported by Bein and co-workers was used[60]. Thus, 170 µL 
of a 2 mg mL-1 nanoparticles suspension was filled into a reservoir cap sealed with a dialysis 
membrane (molecular weight cut-off 12,000 g mol-1), which allows released dye molecules to pass 
into the fluorescence cuvette (that was completely filled with PBS at a given pH) while the 
relatively large particles are held back. Experiments were performed at a temperature of 37 ºC. On 
the other hand, with the aim of carrying out a more realistic experiment pH-responsive 
[Ru(bipy)3]2+ release performance of MSNConA was performed in cell culture media in order to 
mimic the in vitro conditions. These complementary experiments were performed in α-minimum 
essential medium (α-MEM, Sigma Chemical Company) containing 10% of heat-inactivated fetal 
bovine serum (FBS, Thermo Fisher Scientific) and 1% penicillin-streptomycin (BioWhittaker 
Europe, Verviers, Belgium) at two pH values, i.e. 7.4 and 5.3. The experiments were carried out at 
a temperature of 37 ºC during 48 h, which was the time used to accomplish in vitro cytotoxicity 
assays with cells (see Section 2.10). 
2.10. Cell cultures 
Cell culture tests were performed using the well-characterized mouse preosteoblastic cell line 
MC3T3-E1 (subclone 4, CRL-2593; ATCC, Mannassas, VA) and HOS cells derived from a 
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human osteosarcoma (CRL-1543; ATCC, Mannassas, VA). The tested nanoparticles were placed 
into each well of 6- or 24-well plates (Corning, CULTEK, Madrid, Spain) after cell seeding. 
MC3T3-E1 and HOS cells were then plated separately at a density of 20,000 cells cm-2 in 1 mL of 
α-minimum essential medium (MEM) or Dulbecco’s modified Eagle’s medium (DMEM, Sigma 
Chemical Company), respectively, containing 10% of FBS and 1% penicillin–streptomycin at 37 
ºC in a humidified atmosphere of 5% CO2, and incubated for different times. Some wells 
contained no nanoparticles as controls. 
2.11. Cell viability 
Cell growth was analyzed using the CellTiter 96® AQueous Assay (Promega, Madison, WI, 
USA), a colorimetric method for determining the number of living cells in culture. Briefly, both 
type of cells were cultured as described above without (control) or with the tested materials and/or 
different concentrations of ConA for several times. At each time, 40 µL of CellTiter 96 AQueous 
One Solution Reagent (containing 3-(4,5-dimethythizol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-
sul-fophe-nyl)-2H-tetrazoliumsalt (MTS) and an electron coupling reagent (phenazine ethosulfate) 
that allows its combination with MTS to form a stable solution was added to each well and 
incubated for 4 h. The absorbance at 490 nm was then measured in a Unicam UV-500 UV–visible 
spectrophotometer (Thermo Spectronic, Cambridge, UK). 
2.12. Flow cytometry studies 
MC3T3-E1 and HOS cells were cultured separately in each well of a 6-well plate. After 24h, the 
cells were incubated at different times in the absence or presence of the tested nanoparticles (100 
µg mL-1). After 2 h, cells were washed twice with PBS and incubated at 37 ºC with trypsin–EDTA 
solution (Sigma-Aldrich) for cell detachment. The reaction was stopped with culture medium after 
5 min and cells were centrifuged at 1,000 rpm for 10 min and resuspended in fresh medium. Then, 
the surface fluorescence of the cells was quenched with trypan blue (0.4%) to confirm the presence 
of an intracellular, and therefore internalized, fluorescent signal. Flow cytometry measurements 
were performed at an excitation wavelength of 488 nm, green fluorescence was measured at 530 
nm (FL1). The trigger was set for the green fluorescence channel (FL1). The conditions for the 
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data acquisition and analysis were established using negative and positive controls with the 
CellQuest Program of Becton–Dickinson and these conditions were maintained during all the 
experiments. Each experiment was carried out three times and single representative experiments 
are displayed. For statistical significance, at least 10,000 cells were analyzed in each sample in a 
FACScan machine (Becton, Dickinson and Company, USA) and the mean of the fluorescence 
emitted by these single cells was used. 
2.13. Fluorescence microscopy 
Cells were incubated with the MSNs (100 µg mL-1) for 2 h. Each well was washed with cold PBS 
for three more times to get rid of the nanoparticles no internalized into the cells, and then fixed 
with 75% ethanol (kept at -20 ºC) for 10 min. After the ethanol was suck and washed three times 
with cold PBS, actin filaments were stained in red with Alexa Fluor® 555 Phalloidin (Thermo 
Fisher Scientific) for 20 mins at 1:40. The nucleus of both types of cells were stained with 4',6-
diamidino-2-fenilindol (DAPI, ≥ 98%, Sigma-Aldrich)  for 5 min, respectively, and then washed 
three times with cold PBS. Fluorescence microscopy of fluorescein-labelled MSNPAA and 
MSNConA internalized into MC3T3-E1 and HOS cells was performed with an Evos FL Cell 
Imaging System (Thermo Fisher Scientific) equipped with three Led Lights Cubes (λex (nm); λem 
(nm)): DAPI (357/44; 447/60), GFP (470/22; 525/50), RFP (531/40; 593/40) from AMG (Advance 
Microscopy Group). Red channel was used to label the cytoplasm, green for nanoparticles and 
blue for cell nucleus. 
2.14. Measurement of sialic acid levels 
The contents of the resulting free N-acetylneuraminic acid were measured using a sialic acid 
(NANA) fluorometric assay kit (BioVision Inc., Milpitas, CA, USA) according to the 
manufacturer’s instructions, followed by detection and analyses UV-visible. This kit utilizes an 
enzyme coupled reaction in which free sialic acid is oxidized resulting in development of Oxi-Red 
probe to give absorbance (OD = 570 nm). 
2.15. Statistical analysis 
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Results are expressed as mean ± SEM. Statistical evaluation was carried out with nonparametric 
Kruskal-Wallis test and post-hoc Dunn´s test, when appropriate. A value of p<0.05 was considered 
significant. 
 
3. Results and Discussion 
3.1 Preparation and characterization of the nanosystems 
Scheme 1 illustrates the different synthetic steps carried out in this work with the aim of 
assembling the different building blocks in to the DOX-loaded MSNs aimed at developing the 
final multifunctional nanodevice for antitumor therapy. It should be remarked that this is a 
simplified depiction that does not take into account that, during the first synthetic stages, the 
incorporation of organic functions takes place not only on the external surface, but also on the 
internal surface of the nanoparticles, as concluded after materials characterization (vide infra).    
First, surfactant-containing MSN were reacted with TEPSA followed by succinic anhydride 
hydrolysis to attain carboxylic acid moieties on the MSN, affording surfactant-containing 
MSNCOOH. Then, the acid-cleavable linker (ATU) was grafted to such nanoparticles using the well-
known carbodiimide chemistry and the surfactant was removed by solvent extraction, leading to 
MSNATU nanosystem. The next steps consisted in loading the chemotherapeutic drug DOX inside 
the mesoporous cavities (MSNATU@DOX) and proceed to pore capping with the polymer PAA 
(MSNPAA@DOX) to minimize premature cargo release before reaching the acidic environment of 
the endo/lysosomes of the target tumor cell. Finally, ConA was covalently linked to the resulting 
nanosystems, providing MSNConA@DOX. The proposed pH-responsive release behavior of the full 
nanodevice is schematically depicted as an inset in Scheme 1. The pH-dependent stability of this 
acetal linker (ATU) was studied (Fig. S2), remaining stable after 24 h at pH 7.4 while breaking at 
acidic pH of 5.3, in good agreement with the literature [52]. 
With the aim of confirming the chemical grafting of the different functional groups after each step 
of the synthesis, all the nanosystems were deeply characterized after surfactant removal and before 
DOX loading, namely, MSN, MSNCOOH, MSNATU, MSNPAA and MSNConA. 
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FTIR spectra evidence the successful functionalization stages of MSN, since vibration bands 
corresponding to the grafted chemical groups are observed (Fig. 1). FTIR spectrum of MSN 
displays vibration bands in the 490-1090 cm-1 range typical of pure silica materials. MSNCOOH 
FTIR spectrum shows an adsorption peak at 1715 cm-1, owing to the C=O stretching vibration in 
carboxyl group[61]. A slight displacement of C=O stretching vibration (1698 cm-1) and an 
additional absorption band located at 1636 cm-1 characteristic of both primary and secondary 
amide, provided evidence of the satisfactory grafting of ATU[62]. The polymerization is 
evidenced by the presence of a band at 1546 cm-1 characteristic of the asymmetric C-O stretching 
mode of pure PAA[63]. The incorporation of ConA onto the surface does not involve the addition 
of any new functional group but the variation in the proportion of those already present, that is the 
reason because new bands do not appear in the spectrum but the relative intensity of the signals is 
modified showing that reaction takes place.  
The functionalization sequence was monitored by 1H  13C CP-MAS solid-state NMR spectrum 
(Fig. S3, Supporting Information). Compared with pure silica MSN, where only signals 
corresponding to residual surfactant molecules, can be observed, MSNCOOH showed additional 
resonance signals at about 15, 19, 62 and 180 ppm, which can be assigned to characteristic carbon 
peaks of 1,2-bidentate carboxyl groups[61]. The appearance of two signals at 80 and 110 ppm 
demonstrated the presence of dioxane[64] and the presence of a well-defined signal at 175 ppm 
indicates that ATU was covalently attached to MSNCOOH by an amide bond. When the polymer is 
attached onto the surface the two distinct peaks of pure PAA, are observed: one appears at around 
40 ppm and another at 181 ppm[65]. The former is the methine and methylene carbons, and the 
latter is the carboxyl carbon.  
Table 1 summarizes some of the most relevant features of MSN, MSNPAA and MSNConA 
nanosystems synthetized in this work. The differences between TGA measurements allowed 
determining the organic matter content incorporated in each type of nanoparticle. To determine the 
amount of PAA present in MSNPAA sample it was necessary to measure the amount of organic 
matter present in the different samples before polymer incorporation (results not displayed in 
Table 1), i.e. MSN (4.5%) MSNCOOH (21.9%), MSNATU (28.8%) and MSNPAA (36.2%), which 
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allowed estimating a polymer content of ca 7%. Finally, ca. 10 % was the amount of ConA 
existing in the final nanosystem, MSNConA. 
Low-angle XRD patter of MSN display four resolved peaks that can be indexed as 10, 11, 20 and 
21 reflections of a well-ordered 2D-hexagonal structure with p6mm plain group typical of MCM-
41 (Fig. 2). Nonetheless, the intensity of such peaks XRD patters of MSNPAA notably decreases, 
even disappearing that assigned to 21 reflection, whereas those of MSNConA exhibit a unique weak 
signal that can be assigned to 10 reflection. 
These experimental results could be related to a loss of mesostructural order due to the PAA and 
ConA grafting processes in samples MSNPAA and MSNConA, respectively. However, it has been 
widely reported that it is not easy to detect alterations in the crystal structures exclusively from 
powder XRD[66,67]. Actually, the disappearance of the signals in XRD patterns of coated 
nanosystems may be also attributed to the effective filling of the mesopore channels by PAA and 
ConA, as it has been previously reported for MSNs coated with gelatin and decorated in the 
outermost surface with folic acid as targeting ligand[31]. This fact would be in good agreement 
with the results derived from N2 adsorption porosimetry discussed below, where a decrease in the 
textural properties of these nanosystems occurs owing to the organic matter incorporation. 
Moreover, this statement is in agreement with HRTEM studies of the different samples, where the 
preservation of the well-ordered 2D-hexagonal structure can be clearly observed, vide infra. 
 As expected, the textural parameters of nanoparticles (mainly surface area, pore volume and pore 
diameter), derived from N2 adsorption porosimetry experiments, experience a significant decrease 
with increasing surface decoration (Table 1). N2 adsorption-desorption isotherms are of type IV 
corresponding to mesoporous materials (Fig. S4, Supporting Information). The suitable treatment 
of the experimental data evidences a dramatically decrease in the textural properties when ranging 
from MSN to MSNPAA and MSNConA samples, which confirms the successful incorporation of the 
polymer coating and the lectin to the nanoparticles. Thus, the surface area (SBET) decreases from 
1210 m2 g-1 for MSN to 22 m2 g-1 and 15 m2 g-1 for MSNPAA and MSNConA, respectively. The initial 
pore volume (VP) of MSN decreases from 1.41 cm3 g-1 to 0.11 cm3 g-1 and ~ 0 cm3 g-1, for MSNPAA 
and MSNConA, respectively. Finally, the pore diameter (DP) experiences a major decrease dropping 
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from 2.4 nm for MSN to a value that could not be determined in the case of MSNPAA and MSNConA 
samples. For comparison purposes, N2 adsorption-desorption isotherm of MSNATU sample was 
also registered (Fig. S4, Supporting Information), whose appropriate treatment allowed to obtain 
the following parameters: SBET = 607 m2 g-1, VP = 0.78 m2 g-1 and DP = 2.3 nm. These results 
clearly point to a decrease in the surface, pore volume and pore diameter due to the partial 
blocking of the mesopore entrances ascribed to ATU moieties probably grafted both in the outer 
and inner surface of nanoparticles. All these findings may account not only to the external 
polymeric covering of MSN by PAA and ConA, but also to the partial filling of the mesoporous 
cavities, in agreement with XRD results previously discussed.  
TEM images of nanoparticles samples show a honeycomb mesoporous arrangement typical of 
MCM-41 (Fig. 3) Grafting of PAA and ConA does not affect the mesostructural order or MSN. 
The morphology of the nanoparticles is also preserved, showing spherical particles in all cases. 
Staining of samples with 1% PTA permitted to observe the organic matter as high contrast zones 
and the inorganic silica matrix as brighter areas in TEM images. The average diameter of the 
nanosystems estimated from the measurement of 20 nanoparticles was ca 160 nm, 200 and 210 nm 
for MSN, MSNPAA and MSNConA, respectively, with a relative error of ca. 10%. TEM images 
indicate that the average thickness of the organic coating for MSNPAA was ca. 4 nm (as indicated 
in Fig. 3, bottom left), whereas the appearance of small globular aggregates in MSNConA sample 
(yellow arrows in Fig. 3, bottom right) accounts for the presence of the protein decorating the 
polymeric layer.  
To acquire information regarding the mean size and surface charge of the nanosystems, dynamic 
light scattering (DLS) and ζ-potential measurements were recorded (Fig. 3, top left). The mean 
hydrodynamic sizes determined by DLS were found to be 180 nm, 220 nm and 260 nm for MSN, 
MSNPAA and MSNConA, which, as expected, are slightly higher than those estimated from TEM 
images. This fact is explained because DLS provides the mean diameter of nanoparticles with a 
solvation layer[68], whereas TEM shows the size in a dry state[69].   
ζ-potential measurements in water of the different nanoparticles showed notable variations in the 
superficial charge (Fig. S5, Supporting Information), which are consistent with the different 
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functionalities incorporated in each step of the synthesis. The values change from -20.0 mV for 
MSN to -39.2 mV for MSNCOOH because of the incorporation of –COOH groups of TEPSA onto 
the surface of MSN. For MSNATU the ζ-potential increased to -15.0 mV what is also consistent 
with the incorporation of amino groups from ATU. The coating process with an acid polymer 
(PAA) entailed again a decrease in the ζ-potential of the so-called MSNPAA until -54.4 mV 
(MSNPAA). Finally anchoring ConA by amide linkages with the acid groups of the polymer 
resulted in a ζ-potential value of -34.2 mV for the entire system MSNConA. The different ζ-
potencial values obtained account for the successfully PAA grafting and subsequent ConA 
anchorage in MSNPAA and MSNConA, respectively. 
3.2. “In vial” cargo release experiments 
[Ru(bipy)3]2+ was used as model molecule to evaluate the pH-responsiveness of the final 
nanosystem, MSNConA. As indicated in the experimental section, the cargo loading was carried out 
by dispersing 40 mg of MSNATU nanoparticles into a concentrated solution of [Ru(bipy)3]Cl2 (10 
mg mL-1) and stirred at RT for 24 h. Then PAA capping was performed in situ via EDC-NHS 
chemistry. After washing and isolation of molecule-loaded MSNPAA samples, ConA was 
covalently grafted (for further details see experimental section). The estimated amount of 
[Ru(bipy)3]2+ loaded into the nanosystems was found to be 5.9% in weight. In the case of DOX, 
the amount of drug incorporated into the nanoparticles was 6.9% in weight. The decrease in the VP 
derived from N2 adsorption measurements (results not shown) confirms the incorporation of the 
cargoes into the mesoporous channels. The pH-responsive drug delivery behavior of the final 
nanosystem, MSNConA, under physiological relevant conditions mimicking extracellular 
environment (pH 7.4) and those of endosomes or lysosomes (pH ≤ 5.5) [Ru(bipy)3]2+ was 
evaluated “in vial” in two different media: phosphate buffered saline (PBS) and cell culture 
medium. Fig. 4.A shows the cargo release profiles from MSNConA after soaking in a buffered 
solution (PBS 1x) at pH 7.4 and pH 5.3 during 24 h and monitored by fluorescence excitation 
spectroscopy under continuous settings. Release profiles can be adjusted to first-order kinetic 
model by introducing an empirical non-ideality factor (δ) to give the following equation (Eq. 1) 
[70]: 
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Y = A (1–e-kt)δ  (Eq. 1) 
being Y the percentage of [Ru(bipy)3]2+ released at time t, A the maximum amount of [Ru(bipy)3]2+ 
released (in percentage), and k the release rate constant. The values for δ are comprised between 1 
for materials that obeys first-order kinetics, and 0, for materials that release the loaded cargo in the 
very initial time of test. The parameters of the kinetic fitting shown in Fig. 4.A (R2 > 0.99) indicate 
that, whereas the maximum amount of [Ru(bipy)3]2+ released is ca. 71% of the total loaded 
molecule at pH = 5.3 after 24 h of assay, a notable amount of the cargo is retained at pH 7.4. At 
the two pH values tested, the obtained δ values are very similar, in the 0.7–0.8 range, pointing to a 
near first order kinetics with a slight contribution of an initial burst release of the loaded 
molecules. Nonetheless, at pH 5.3 the total molecule release is almost 3-fold higher than that at pH 
7.4, which is associated to a k value twice greater under acidic conditions. The two modal release 
curves owing to the two different slopes obtained in the same delivery curve at both pH values 
could be explained by taking into account that the characterization of the different materials points 
to the functionalization not only of the external but also of the porous internal structure of MSN. 
Thus, the [Ru(bipy)3]2+ release mechanism would be a combination of simple diffusion of 
molecules not being affected by the presence of the ATU linker, with acid-triggered linkage 
delivery. 
With the aim of getting information about cargo release performance of MSNConA nanosystem 
under more realistic conditions mimicking the in vitro conditions, additional “in vial” 
[Ru(bipy)3]2+ release assays in cell culture media were carried out. These complementary 
experiments were performed in α-MEM containing 10% of heat-inactivated FBS and 1% 
penicillin-streptomycin at two pH values, i.e. 7.4 and 5.3, as described in the experimental section. 
The amount of molecule released to the complemented culture media was monitored during 48 h 
of assay, which was the time used for the in vitro cytotoxicity studies with DOX-loaded 
nanoparticles. The results are displayed in Fig. 4.B. In this case, the molecule release profiles at 
both pH values are totally different to those obtained in PBS, and they  can be properly adjusted to 
zero-order or linear kinetics (R2 > 0.99) according to Eq. 2: 
Y = B + kt  (Eq. 2) 
  
19 
 
 being Y the percentage of [Ru(bipy)3]2+ released at time t, B the amount of [Ru(bipy)3]2+ released 
(in percentage) at t = 0, and k the release rate constant. The parameters of the kinetic fitting 
displayed in Fig. 4.B indicate that the amount of molecule release at t = 0 is almost depreciable at 
both pH values. After 48 h of assay only ca. 5% of molecule is released from MSNConA at pH 7.4, 
whereas almost 30% of the entrapped Ru(II) complex is released at pH 5.3, i.e. the amount of 
released cargo is 6-fold higher under acidic conditions than at physiological pH. This fact agrees 
with the release rate constant, which is 5 times faster at pH 5.3 than at pH 7.4, with values of 0.555 
h-1 and 0.112 h-1, respectively.        
When comparing the results obtained in protein-free PBS media (Fig. 4.A) with those in protein-
containing media (Fig. 4.B), the more remarkable aspects concern both the modification in the 
molecule release profiles and the maximum amount of released cargo. The results obtained in 
complemented α-MEM point to the coverage of the nanoparticles by a series of proteins from 10% 
FBS through a process called “protein corona effect”[71]. The formation of a “protein corona” 
onto the surface of the nanoparticles can shield the nanocarriers, thus partially blocking the 
mesopore entrances and, consequently, altering the cargo release profiles [72]. Herein, the protein 
corona would be significantly reducing the burst effect and provoking a more-sustained release of 
the entrapped [Ru(bipy)3]2+ than in protein-free PBS media.    
3.2. In vitro biological evaluation 
Once MSNConA sample was deeply characterized and its pH-sensitive drug release capability was 
proved “in vial”, we proceeded to investigate its in vitro performance as selective drug delivery 
nanocarrier. To evaluate the in vitro biological behavior of our nanosystem and its potential 
application in bone cancer treatment, nanoparticles were incubated in the presence of two types of 
bone cells populations: MC3T3-E1 preosteoblastic cell line, and HOS human osteosarcoma cells. 
Herein, the grafting of ConA to the outermost surface of our nanosystems aims at playing a key 
role, acting as targeting ligand that permits the selective internalization of the nanocarrier by bone 
cancer cells and not by healthy ones. Once there, the acidic environment of the endo/lysosomes 
cellular compartments would trigger the release of the cytotoxic cargo.  
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The first step consisted in evaluating the capability of ConA-conjugated (MSNConA) and ConA-free 
(MSNPAA) nanoparticles to be internalized by MC3T3-E1 and HOS cells. To attain this goal, both 
types of nanoparticles were labelled with fluorescein, as previously described in the experimental 
section. Cellular uptake and internalization of fluorescein-labelled MSNConA and MSNPAA 
nanoparticles were investigated by flow cytometry and fluorescence microscopy in MC3T3-E1 
and HOS cells in contact with (100 µg mL-1) for 2 h (Fig. 5). After 2 h of cell culture, MSNConA 
internalization and fluorescence intensity in HOS cells significantly increase compared to 
MSNPAA, and they are always higher than those in MC3T3-E1 cells.  
The cellular uptake results obtained by flow cytometry were also confirmed by fluorescence 
microscopy using fluorescein-labelled nanoparticles after 2 h (representative images in Fig. 6). 
The highest amount of internalized nanoparticles corresponds to MSNConA ones after being in 
contact with HOS osteosarcoma cells. Notice that, in this case, there is a perceptible variation in 
the morphology and disposition of actin filaments, which make us hypothesizing that those cells 
may be in a preapoptotic state (Fig. 6). This finding could be attributed to some cellular damage 
that ConA may be exerting in HOS cells (see Fig. S6, Supporting Information), as reported in the 
literature for various cancer cell lines[73-75]. Nonetheless, no significant cell viability decrease 
has been observed during cytotoxicity assays by MTS for MSNConA concentrations up to 144 µg 
mL-1 (Fig. S7, Supporting Information). 
The next step was to investigate the ligand-receptor interactions that would be promoting 
preferential MSNConA internalization into HOS cancer cells. In this context, in recent years, sialic 
acids, a type of glycans attached to glycoproteins on the cell, have been studied as disease-
associated carbohydrate derivatives, because their expression provides many opportunities for the 
appraisal of the cell processes[76,77]. For instance, Cho et al. designed lectin-tagged fluorescent 
polymeric nanoparticles as potential bioimaging probes for detecting diseased cells by the union 
lectin-sialic acids[78]. Through cellular experiments, they successfully detected sialic acid 
overexpression on cancerous cells with high specificity.  
Thus, to confirm the possible overexpression of sialic acid in HOS cells compared with MC3T3-
E1 cells, and their interaction with ConA, we measured the N-acetylneuraminic acid levels. This 
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acid is the most common member of sialic acid derivatives and is found widely distributed in 
animal tissues. We found that N-acetylneuraminic acid levels in HOS cells were significantly 
higher than in MC3T3-E1 cells: 600 ± 1 nmol µg-1 protein in HOS cells vs. 100 ± 2 nmol µg-1 
protein in MC3T3-E1 cells. These results suggest that the presence of ConA in the surface of the 
nanoparticles allows the binding with sialic acid and improving the selective internalization of 
MSNConA in HOS cells where the sialic acid levels were 6-fold increased. It is true that MSNConA 
can be uptaken by non-tumor MC3T3-E1 cells that are non-overexpressing sialic acid, but this 
internalization rate was always higher in HOS cells. Therefore, our group and others have 
previously demonstrated that MC3T3-E1 cells internalized itself different types of nanoparticles 
[30,31,36,79,80] Moreover, probably this N-acetylneuraminic acid levels overexpression is not the 
only mechanism implicated in the high rate of MSNConA internalization. Further studies are 
needed to confirm these hypotheses. 
Once demonstrated the capability of MSNConA nanoparticles to be preferentially internalized by 
HOS cells than by MC3T3-E1 cells, the next goal was to investigate and compare the in vitro 
performance of DOX-loaded lectin-conjugated (MSNConA@DOX) and lectin-free 
(MSNPAA@DOX) nanosystems in cultures of both cell types at different nanoparticles 
concentrations. However, evaluating the killing capability of free DOX towards both cell types is 
necessary to compare the efficiency and selectivity of the here developed nanotransporter. Thus, 
different amounts of free DOX (0, 2.5, 5, 10 and 20 µg mL-1) were used, and the results indicate 
that cell death induced by DOX is very high and shows a linear dose-dependent concentration both 
in preosteoblastic MC3T3-E1 and osteosarcoma HOS cells (Fig. S8, Supporting Information). This 
accounts for the high and unselective cytotoxicity of this drug.   
Then, we performed and in vitro cytotoxicity study (by a MTS assay) with DOX concentrations 
(2.5 and 10 µg mL-1) incorporated in MSNConA and MSNPAA nanoparticles in the presence of 
MC3T3-E1 or HOS cells at 48 h (Fig. 7). Comparing the toxicity of MSNConA@DOX vs. that of 
MSNPAA@DOX, it is observed that MSNConA@DOX causes increased cell death than 
MSNPAA@DOX, and that this increase is much more significant in HOS cells that in MC3T3-E1. 
Actually, it should be highlighted that this effect is much more obvious at very low DOX 
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concentrations (2.5 µg mL-1). Thus, after 48 h of assay MC3T3-E1 cells does not experience any 
cytotoxic effect after being incubated with 2.5 µg mL-1 of DOX loaded in both nanosystems. 
Oppositely, HOS cells viability decreases to ca. 40% after exposition to 2.5 µg mL-1 of drug 
loaded into MSNPAA. This value is quite similar to that for HOS cells after exposure to free DOX 
(Fig. S8, Supporting Information). Nonetheless, the antitumor effect of MSNConA towards HOS 
cells increases 8-fold compared to MSNPAA (Fig. S8, Supporting Information). 
 
4. Conclusions 
In this work we have developed a multifunctional nanodevice featuring selectivity towards human 
osteosarcoma cells and pH-responsive antitumor drug delivery capability. The synergistic 
combination of both properties into a unique nanosystem produces an amplification of the 
antitumor efficacy.  
This innovative nanodevice is based in DOX-loaded MSNs nanoplatforms where different 
building blocks are assembled: i) a PAA polymeric shell, anchored via an acid cleavable linker, to 
prevent premature cargo release and provide the nanosystem of pH-responsive capability; ii) a 
targeting ligand consisting in the lectin ConA grafted to PAA, to increase the selectivity towards 
cancer cells whereas significantly preserving the viability of healthy cells.  
In vitro assays reveal that the internalization degree of lectin-conjugated nanosystems into human 
osteosarcoma cells is 2 times higher than in human preosteoblastic cells. Moreover, only very 
small DOX concentrations (2.5 µg mL-1) are needed to attain ca 100% antitumor efficacy against 
osteosarcoma cells compared to healthy bone cells, whose viability is preserved. Moreover, the 
antitumor effect is increased up to 8-fold compared to that caused by the free drug.  
These outcomes prove that the synergistic assembly of different building blocks into a unique 
nanoplatform increases antitumor effectiveness and decreases toxicity towards healthy cells, which 
constitutes a new paradigm in targeted bone cancer therapy. 
Apendix A. Supplementary data 
Supplementary data associated with this article can be found in the online version. 
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Figure captions 
Scheme 1. Schematic illustration of the synthetic steps involved in the formation of 
tumor-targeted DOX-loaded nanosystem (MSNConA@DOX) consisting of MSNs 
encapsulating DOX, grafted with a pH-cleavable linker (ATU), coated with an acid-
degradable polymer (PAA) and covalently linked to the lectin ConA to obtain the final 
nanodevice. The pH-responsive behavior of the nanocarrier is depicted as an inset.  
Fig. 1. FTIR spectra of the different nanosystems synthetized in this work. 
Fig. 2. Low-angle XRD patterns of the different nanosystems synthetized in this work. 
Fig. 3. Hydrodynamic size, measured by DLS, and TEM images of the different 
nanosystems synthetized in this work. To carry out TEM studies samples were stained 
with 1% of phosphotungstic acid (PTA). 
Fig. 4. “In vial” release profiles of [Ru(bipy)3]2+ model molecule from MSNConA 
nanodevices when soaked in: A) phosphate saline solution (PBS) at pH 7.4 and 5.3 for 24 
h; and B) α-MEM containing 10% of heat-inactivated FBS and 1% penicillin-
streptomycin at pH 7.4 and 5.3 for 48 h. 
Fig. 5. Cellular uptake (A) and fluorescence intensity (B) of fluorescein-labeled MSNPAA 
and MSNConA nanosystems measured by flow cytometry at 2 h of cell culture of MC3T3-
E1 and HOS cells. Representative flow cytometry images are shown (A). Data are mean ± 
SEM of 3 independent experiments performed at least in triplicate *p < 0.05 vs. 
corresponding control without nanoparticles; **p < 0.05 vs. corresponding control with 
nanoparticles; #p < 0.05 vs. corresponding and same condition in MC3T3-E1 cells. 
Fig. 6. Representative fluorescence microscopy images of MC3T3-E1 and HOS cells 
incubated with fluorescein-labeled MSNPAA and MSNConA nanosystems at 2 h of cell 
culture. Blue fluorescence (nuclei), red (actin filaments), green fluorescence (fluorescein 
labeled nanoparticles). 
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Fig. 7. Cytotoxicity assay measured by MTS reduction in MC3T3-E1 and HOS cells with 
different concentrations (2.5 and 10 µg mL-1) of DOX-loaded MSNPAA and MSNConA 
nanosystems at 48 h of cell culture. Data are mean ± SEM of 3 independent experiments 
performed at least in triplicate. #p < 0.05 vs. 2.5 µg/mL corresponding DOX-loaded 
nanosystems; *p < 0.05 vs. 10 µg/mL vs. corresponding DOX-loaded nanoparticles; **p < 
0.05 vs. corresponding and same condition in MC3T3-E1 cells. 
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Table 1. Main properties of nanosystems synthetized in this work.  
 
Material MSN MSNPAA MSNConA 
Organic matter (TGA) (%) 4.5 ± 0.1 36.2 ± 0.7 46.5 ± 0.9 
SBET (m2 g-1) 1210 ± 35 22 ± 1 12 ± 1 
VP (cm3 g-1) 1.41 ± 0.03 0.11 ± 0.01 ~ 0 
DP (nm) 2.4 ± 0.1 - - 
ζ-potential (mV) -20.0 ± 1.0 -54.4 ± 4.0 -34.2 ± 0.5 
Mean size (DLS) (nm) 180 ± 5 220 ± 8 260 ± 10 
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